Shots:
- Immutep has reported Cohort B data from P-IIb (KEYNOTE-C34/ TACTI-003) trial, with Cohort B assessing eftilagimod alfa + Keytruda as a 1L treatment of recurrent/metastatic HNSCC pts with PD-L1 expression (CPS <1)
- As of Mar 31, 2025, trial showed improved mOS of 17.6mos. in evaluable pts (n=31) compared to historical mOS of cetuximab + CT (10.7mos.), anti-PD-1 therapy + CT (11.3mos.), & anti-PD-1 monotx. (7.9mos.)
- Immutep has requested an FDA meeting to discuss potential approval paths for 1L HNSCC with PD-L1 CPS <1, plus follow-up, data collection, & analysis will continue for TACTI-003, with an update expected later this year
Ref: GlobeNewsWire | Image: Immutep
Related News:- Merck Reports P-III (KEYNOTE-689) Trial Data of Perioperative Keytruda for Locally Advanced Head and Neck Squamous Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
